KALA BIO (KALA) Expected to Announce Quarterly Earnings on Thursday

KALA BIO (NASDAQ:KALA) will likely be posting its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect KALA BIO to post earnings of ($2.47) per share for the quarter.

KALA BIO Trading Down 2.5 %

NASDAQ KALA opened at $7.03 on Thursday. The stock has a market capitalization of $42.82 million, a price-to-earnings ratio of -0.56 and a beta of -2.19. KALA BIO has a one year low of $4.21 and a one year high of $11.20. The company has a debt-to-equity ratio of 3.18, a current ratio of 2.15 and a quick ratio of 2.15. The business’s fifty day moving average is $7.74 and its 200-day moving average is $6.77.

Insider Transactions at KALA BIO

In related news, CEO Mark T. Iwicki sold 5,779 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $7.63, for a total value of $44,093.77. Following the sale, the chief executive officer now directly owns 280,076 shares in the company, valued at approximately $2,136,979.88. The trade was a 2.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Bros. Advisors Lp Baker acquired 310,559 shares of the stock in a transaction that occurred on Monday, December 30th. The stock was purchased at an average price of $6.44 per share, for a total transaction of $1,999,999.96. Following the completion of the purchase, the insider now directly owns 1,083,398 shares in the company, valued at $6,977,083.12. This trade represents a 40.18 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold 9,506 shares of company stock worth $72,531 in the last ninety days. Company insiders own 8.32% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of KALA BIO in a research note on Thursday, February 13th.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.